



International Summit on Psychedelic Therapies for Mental Illness 17-20 November 2021

We are delighted to extend an invitation to you and your colleagues to join us ONLINE in November 2021.

Mind Medicine Australia will hold a two-day **International Summit on Psychedelic Therapies for Mental Illness** in November 2021 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy leaders, business, industry, insurers, consumers and other interested stakeholders.

The event will also feature a two-day pre-Summit **Introductory Workshop Program (17-18 November)** led by **Nigel Denning, Dr Tra-ill Dowie with world-leading therapist trainer Dr Bill Richards (USA) from Johns Hopkins University.** It is for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of **psychedelic-assisted psychotherapy for the treatment of mental illness.**

The program features a world class line-up of talks, workshops, hot spots, panel conversations and creative moments.

Leading international speakers confirmed for the 2-day summit and Mind Medicine Australia Ambassadors include: **Professor David Nutt (UK)** Head of Neuropsychopharmacology at Imperial College London and lead advisor on psilocybin assisted therapy for treatment-resistant depression, **Dr Gabor Maté (Canada)** renowned trauma and addiction physician, **Johann Hari (UK)** journalist and bestselling author, **Dr Bill Richards (USA)** world-leading therapist trainer and psychologist at the Johns Hopkins School of Medicine, **Dr Ben Sessa (UK)** psychiatrist, researcher and writer and currently leading the Imperial College trials on using MDMA therapy for alcohol dependence, **Dr Robin Carhart-Harris (UK)** Head of the Centre for Psychedelic Research at Imperial College London, **Francoise Bourzat (USA)** Counsellor and Author, **Wade Davis (Canada)** anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society, **Dr Alberto Villoldo (USA)** medical anthropologist and author, **Dr Lynn Marie Morski (USA)** President of the Psychedelic Medicine Association, **Matthew Johnson (USA)** Professor of Psychiatry and Behavioural Sciences at Johns Hopkins University School of Medicine with a focus on psychedelic research for the treatment of mental illness, **Dr Adele Lafrance (USA/Canada)** Clinical Psychologist and Research Scientist, **Patrycja Slawuta (USA)** Researcher & Psychologist, **Dr Gabby Agin-Liebes (USA)** Psilocybin researcher at Weill Institute for Neuroscience, **Admiral Chris Barrie AC (AUS)** former Head of the Australian Defence Force and Strategic Leadership Consultant, **Dr Kate Pate (USA)** Neurophysiologist and writer, **Arthur Christopoulos (AUS)** Professor of Analytical Pharmacology and Molecular Neuropsychopharmacologist at Monash University, **Dr Reid Robinson (USA)** psychedelic psychiatrist and writer, **Dr Adam Gazzaley (USA)** Founder & Executive Director of Neuroscape, **Shlomi Raz (USA)** Chairman and CEO of Eleusis, **Kelsey Ramsden (Canada)** Co-Founder, CEO & President of Mindcure, **John Skerritt (AUS)** Deputy Secretary, Health Products Regulation Group - TGA, **Dr Simon Longstaff (AUS)**



Executive Director of The Ethics Centre, **Dr Eli Kotler (AUS)** Psychiatrist and Director of Medicine at Malvern Private Hospital... and more to be announced.

Key themes will include:

- The current state of mental health in Australia, existing treatments and the need for innovation
- The Science of Psychedelics: Therapeutic mechanisms and clinical outcomes for a range of mental illnesses and other conditions
- Indigenous Wisdom and expanded states of consciousness for healing and growth
- Depression, Trauma, Addiction and Suicide: Prevention is better than cure
- Living until you die: the promise of psilocybin-assisted therapy for end-of-life
- The way forwards for Australia: Ethical, legal, and implementation frameworks for psychedelic treatments and a new paradigm for treatment of mental illness
- Creating the Future: What the Psychedelic Industry Will Look Like 5 Years Out?

Psychedelic therapies have been granted **Breakthrough Therapy status by the FDA in the USA** due to current promising research in the **treatment of depression and PTSD**. We look forward to collaborating with you to explore psychedelic treatment options to help address the **mental health epidemic we currently face, and offer treatments to those who need it most**.

Together we can change the treatment paradigm and create a healthier, happier future.

For more details and to register for tickets, please visit:

<https://summit.mindmedicineaustralia.org/>